Caribou Biosciences, Inc. (CRBU)
| Market Cap | 201.97M |
| Revenue (ttm) | 11.16M |
| Net Income (ttm) | -148.13M |
| Shares Out | 96.64M |
| EPS (ttm) | -1.59 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,135,213 |
| Open | 2.120 |
| Previous Close | 2.130 |
| Day's Range | 2.055 - 2.160 |
| 52-Week Range | 0.730 - 3.535 |
| Beta | 2.46 |
| Analysts | Strong Buy |
| Price Target | 10.75 (+414.35%) |
| Earnings Date | May 8, 2026 |
About CRBU
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCM... [Read more]
Financial Performance
In 2025, Caribou Biosciences's revenue was $11.16 million, an increase of 11.66% compared to the previous year's $9.99 million. Losses were -$148.13 million, -0.66% less than in 2024.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for CRBU stock is "Strong Buy." The 12-month stock price target is $10.75, which is an increase of 414.35% from the latest price.
News
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy
-- RMAT granted based on promising initial clinical data, including previously disclosed recommended dose for expansion data of 92% ORR, 75% ≥CR rate, 91% MRD negativity in the 12-patient, BCMA-naïve ...
Caribou Biosciences Transcript: Leerink Global Healthcare Conference 2026
Key clinical updates include pivotal trial planning for vispa-cel and expansion of CB-011, with robust FDA engagement and a focus on scalable, low-cost manufacturing. Financing will blend equity and partnerships, while commercialization will be direct in the U.S. and partner-driven globally.
Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
BERKELEY, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial result...
Caribou Biosciences Transcript: Citi’s 2026 Virtual Oncology Leadership Summit
The summit highlighted advances in allogeneic CAR-T therapies, with pivotal-ready programs for lymphoma and myeloma showing strong efficacy and safety. Upcoming pivotal trials target large unmet needs, with broad access strategies and commercial launches planned.
Watchmaker Genomics Licenses CRISPR-Cas9 Intellectual Property from Caribou Biosciences to Increase Throughput and Reduce Sequencing Cost per Sample
BOULDER, Colo.--(BUSINESS WIRE)-- #NGS--Watchmaker Genomics, an innovator in high-performance solutions for next-generation sequencing (NGS), today announced a non-exclusive license with Caribou Biosc...
Caribou Biosciences to Participate in Upcoming Investor Conferences
BERKELEY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced management will ...
Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR®
Clinical data disclosed in November 2025 to be presented at medical meeting with new supportive translational data for both programs Vispa-cel (CB-010) ANTLER phase 1 translational and clinical data d...
Caribou Biosciences Transcript: The 67th American Society of Hematology (ASH) Annual Meeting
Vispa-cel, an off-the-shelf CAR T-cell therapy, demonstrates efficacy and safety comparable to autologous CAR T, with the potential to address major access barriers for large B-cell lymphoma patients. Community and academic experts anticipate a paradigm shift if approved, expanding curative options to underserved populations.
Caribou Biosciences Transcript: Evercore ISI 8th Annual HealthCONx Conference
Vispa-cel shows auto CAR-T-like efficacy and safety in dual ineligible lymphoma patients, with scalable manufacturing and rapid availability. Regulatory and market access strategies target broad adoption in community centers, while CB-011 in myeloma aims to match bispecifics and expand patient access.
Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025
BERKELEY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it will hos...
Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
Vispa-cel (CB-010) ANTLER phase 1 data demonstrate efficacy and durability on par with autologous CAR-T cell therapy and safety allows for outpatient use, highlighting its potential as a best-in-class...
Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today>
Caribou Biosciences Inc. (NASDAQ:CRBU) stock surged on Monday. The company said the CAR-T therapy induced complete and durable remissions in patients with advanced B-cell lymphoma.
Caribou Biosciences Transcript: Study Result
Phase I data show vispa-cel and CB-011, both allogeneic CAR-T therapies, deliver efficacy and safety on par with autologous CAR-T, with rapid, scalable manufacturing and potential to greatly expand patient access in lymphoma and myeloma.
Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma
BERKELEY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced its first clinic...
Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies
Data demonstrate efficacy and durability of vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy, are on par with autologous CAR-T cell therapies in the confirmatory cohort (N=22) and with longer-ter...
Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma
BERKELEY, Calif., Nov. 02, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it will hol...
Caribou Biosciences Transcript: Citi's Biopharma Back to School Conference
Significant data readouts for two off-the-shelf CAR T cell therapies in lymphoma and myeloma are expected by year-end, with pivotal trial strategies to be announced following FDA discussions. The company’s scalable manufacturing and distribution platform supports broad access, and international trial expansion is underway.
Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference
BERKELEY, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz,...
Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update
-- Two robust clinical datasets from CB-010 and CB-011 expected to be disclosed in H2 2025 -- -- $184 million in cash, cash equivalents, and marketable securities expected to fund the Company's curre...
Caribou Biosciences Transcript: Jefferies Global Healthcare Conference 2025
Two off-the-shelf CAR-T therapies for lymphoma and myeloma are advancing, with key data readouts and pivotal trial plans expected in the second half of the year. Manufacturing and financial resources are in place to support clinical and regulatory milestones into 2027.
Caribou Biosciences to Participate in the Jefferies Global Healthcare Conference
BERKELEY, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, ...
Caribou Biosciences Transcript: Bank of America 2025 Healthcare Conference
The focus is now on advancing CB-010 for lymphoma and CB-011 for myeloma, with both programs showing promising efficacy and durability. Allogeneic CAR-Ts aim to match or exceed current therapies in response rates and offer scalable, off-the-shelf solutions for broader patient access.
Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update
-- Two robust clinical datasets from CB-010 and CB-011 expected to be disclosed in H2 2025 -- -- $212.5 million in cash, cash equivalents, and marketable securities expected to fund the Company's cur...
Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference
BERKELEY, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, ...
Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs
-- Strategic pipeline prioritization with workforce and cost reductions expected to extend the company's cash runway by one year into H2 2027 -- -- Two robust clinical datasets from CB-010 and CB-011 ...